Get the latest news, insights, and market updates on ADPT (Adaptive Biotechnologies Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / Dec 30, 2025 - $ADPT
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat Dec 15, 2025 - $ADPT
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care
Earlier this month, Adaptive Biotechnologies reported that its clonoSEQ test featured in 90 abstracts at the 67th American Society of Hematology (ASH) Annual Meeting, including 17 studies where next-generation sequencing-based measurable residual disease (MRD) results were used to guide treatment decisions in blood cancers. Among the research, phase III AURIGA data in multiple myeloma linked deep and sustained MRD negativity to improved progression-free survival, suggesting clonoSEQ may be... Dec 15, 2025 - $ADPT
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed. Dec 11, 2025 - $ADPT
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology wi Dec 9, 2025 - $ADPT
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake
We recently published December Disappointments: 10 Big Names Troubled Early. Adaptive Biotechnologies Corp. (NASDAQ:ADPT) is one of the worst performers of last week. Adaptive Biotechnologies fell by 24.5 percent week-on-week as investors took path from three key executives’ disposition of a significant stake in the company. In separate regulatory filings last week, Adaptive Biotechnologies Corp. […] Dec 8, 2025 - $ADPT
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ® test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6–9, 2025, in Orlando. Notably, 17 abst Dec 6, 2025 - $ADPT
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback
Adaptive Biotechnologies (ADPT) has quietly turned into a powerful comeback story, with the stock up almost 180% over the past year, even as the business still runs at a loss. See our latest analysis for Adaptive Biotechnologies. The recent pullback, including a 1 day share price return of minus 8.35 percent and a 7 day share price return of minus 13.13 percent, comes after a powerful run in which the 90 day share price return is 31.57 percent and the 1 year total shareholder return is 178.99... Dec 4, 2025 - $ADPT
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug developmentSEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for Nov 24, 2025 - $ADPT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple